BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20098293)

  • 21. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion therapy to everolimus in renal transplant recipients: results after one year.
    Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.
    Lorber MI; Ponticelli C; Whelchel J; Mayer HW; Kovarik J; Li Y; Schmidli H
    Clin Transplant; 2005 Apr; 19(2):145-52. PubMed ID: 15740547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus for cardiac allograft vasculopathy--every patient, at any time?
    Patel JK; Kobashigawa JA
    Transplantation; 2011 Jul; 92(2):127-8. PubMed ID: 21555972
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience.
    Chou NK; Jan CF; Chi NH; Lee CM; Wu IH; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Chu SH; Wang SS
    Transplant Proc; 2012 May; 44(4):897-9. PubMed ID: 22564578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience.
    Hsu KH; Chou NK; Tsai MK; Chi NH; Chen YS; Yu HY; Wang CH; Ko WJ; Tsao CI; Lee PH; Wang SS
    Transplant Proc; 2010 Apr; 42(3):934-7. PubMed ID: 20430208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):252-8. PubMed ID: 14742990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR inhibitors: do they help preserve renal function?
    Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
    Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
    Pascual J; Fernández AM; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.
    Sanchez V; Delgado JF; Morales JM; Tello R; Gómez MA; Escribano P; de la Cámara AG; de la Calzada CS
    Transplant Proc; 2004 Nov; 36(9):2823-5. PubMed ID: 15621159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
    J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching immunosuppressive drugs in kidney transplant recipients: "show me the evidence".
    Ansari MJ; Sayegh MH
    Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):149-52. PubMed ID: 16903619
    [No Abstract]   [Full Text] [Related]  

  • 40. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
    J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.